|
|
||||||||
TRANSLATIONAL PHYSIOLOGY
Department of Surgery, University of Wisconsin Medical School, and University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin
Submitted 29 March 2005 ; accepted in final form 14 June 2005
ABSTRACT
Gastrointestinal (GI) carcinoid cells secrete multiple neuroendocrine (NE) markers and hormones including 5-hydroxytryptamine and chromogranin A. We were interested in determining whether activation of the Notch1 signal transduction pathway in carcinoid cells could modulate production of NE markers and hormones. Human pancreatic carcinoid cells (BON cells) were stably transduced with an estrogen-inducible Notch1 construct, creating BON-NIER cells. In the present study, we found that Notch1 is not detectable in human GI carcinoid tumor cells. The induction of Notch1 in human BON carcinoid cells led to high levels of functional Notch1, as measured by CBF-1 binding studies, resulting in activation of the Notch1 pathway. Similar to its developmental role in the GI tract, Notch1 pathway activation led to an increase in hairy enhancer of split 1 (HES-1) protein and a concomitant silencing of human Notch1/HES-1/achaete-scute homolog 1. Furthermore, Notch1 activation led to a significant reduction in NE markers. Most interestingly, activation of the Notch1 pathway caused a significant reduction in 5-hydroxytryptamine, an important bioactive hormone in carcinoid syndrome. In addition, persistent activation of the Notch1 pathway in BON cells led to a notable reduction in cellular proliferation. These results demonstrate that the Notch1 pathway, which plays a critical role in the differentiation of enteroendocrine cells, is highly conserved in the gut. Therefore, manipulation of the Notch1 signaling pathway may be useful for expanding the targets for therapeutic and palliative treatment of patients with carcinoid tumors.
human achaete-scute homolog-1; neuroendocrine tumors
This article has been cited by other articles:
![]() |
J. T. Adler, M. Cook, Y. Luo, S. C. Pitt, J. Ju, W. Li, B. Shen, M. Kunnimalaiyaan, and H. Chen Tautomycetin and tautomycin suppress the growth of medullary thyroid cancer cells via inhibition of glycogen synthase kinase-3{beta} Mol. Cancer Ther., April 1, 2009; 8(4): 914 - 920. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-C. Wang, E. Gallego-Arteche, G. Iezza, X. Yuan, M. R Matli, S.-P. Choo, M. B Zuraek, R. Gogia, F. C Lynn, M. S German, et al. Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors Endocr. Relat. Cancer, March 1, 2009; 16(1): 267 - 279. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Xiao, L. Ning, and H. Chen Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors Mol. Cancer Ther., February 1, 2009; 8(2): 350 - 356. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. N. Pinchot, K. Holen, R. S. Sippel, and H. Chen Carcinoid Tumors Oncologist, December 1, 2008; 13(12): 1255 - 1269. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Ning, D. Y. Greenblatt, M. Kunnimalaiyaan, and H. Chen Suberoyl Bis-Hydroxamic Acid Activates Notch-1 Signaling and Induces Apoptosis in Medullary Thyroid Carcinoma Cells Oncologist, February 1, 2008; 13(2): 98 - 104. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Y. Greenblatt, A. M. Vaccaro, R. Jaskula-Sztul, L. Ning, M. Haymart, M. Kunnimalaiyaan, and H. Chen Valproic Acid Activates Notch-1 Signaling and Regulates the Neuroendocrine Phenotype in Carcinoid Cancer Cells Oncologist, August 1, 2007; 12(8): 942 - 951. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kunnimalaiyaan and H. Chen Tumor Suppressor Role of Notch-1 Signaling in Neuroendocrine Tumors Oncologist, May 1, 2007; 12(5): 535 - 542. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kunnimalaiyaan, A. M. Vaccaro, M. A. Ndiaye, and H. Chen Inactivation of glycogen synthase kinase-3{beta}, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells Mol. Cancer Ther., March 1, 2007; 6(3): 1151 - 1158. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |